Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin

Exclusion Criteria

• •History of cardiovascular disease: congestive heart failure (CHF) \> New York Heart Association (NYHA) II, active coronary artery disease(patients with myocardial infarction six months ago can be recruited), arrhythmias need to be treated (allow taking beta blockers or digoxin).
• •Serious clinical infection (\> NCI-CTCAE version 4.0 ,infection standard II).
• •Patients with epilepsy who need to take medicine (such as steroids or anti epilepsy agents).
• •with brain metastases.
• •The patients had accepted allogeneic organ transplantation.
• •Bleeding tendency or coagulation disorders.
• •patients who need renal dialysis.
• •suffered from other tumor within 5 years( Except: cervical carcinoma in situ, cured basal cell carcinoma, cured bladder epithelial tumor).
• •uncontrolled hypertension (systolic pressure\>150 mmHg , or diastolic pressure\> 90 mmHg).
• •thrombosis or embolism(cerebrovascular accidents including transient ischemic attack within the last 6 months).
• •pulmonary hemorrhage \>CTCAE grade 2 within 4 weeks before first use of drugs.
• •Other organ hemorrhage \>CTCAE grade 3 within 4 weeks before first use of drugs.
• •severe uncured wounds, ulcers or fracture.
• •uncured dehydration.
• •Drugs abuse and medical, psychological or social conditions may interfere with the patient's participation in research or the results of the evaluation effect.
• •Patients are allergic to drugs used in research.
• •Factors influencing the safety and compliance of patients.
• •Inability to comply with protocol or study procedures.
• •Pregnant or breast-feeding.
• •The researcher believe that the Patient is not suitable to participate in the study.